Revvity Inc Stock Price, News & Analysis

Revvity (NYSE: RVTY) reported strong Q1 2025 financial results with revenue reaching $665 million, representing 2% reported growth and 4% organic growth. The company's GAAP EPS increased to $0.35 from $0.21 year-over-year, while adjusted EPS from continuing operations reached $1.01.

By segment, Life Sciences revenue grew 1% to $340 million with 2% organic growth and improved adjusted operating margin to 31.1%. Diagnostics revenue increased 3% to $324 million with 5% organic growth, though adjusted operating margin decreased to 22.8%.

The company reaffirmed its full-year 2025 organic growth guidance of 3-5% and adjusted EPS guidance of $4.90-$5.00, while raising its revenue guidance to $2.83-$2.87 billion due to foreign currency exchange rate changes.

Revvity (NYSE: RVTY) has announced its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on August 8, 2025 to shareholders of record as of the close of business on July 18, 2025.

Revvity (NYSE: RVTY) has scheduled its first quarter 2025 financial results announcement for Monday, April 28, 2025, before market open. The company will hold a conference call at 8:00 a.m. ET on the same day to discuss the results. CEO Prahlad Singh and CFO Max Krakowiak will host the call, which will be accessible via live audio webcast through the Investors section of Revvity's website.

Revvity (NYSE: RVTY) has received FDA approval for its Auto-Pure 2400 liquid handling platform integrated with the T-SPOT.TB test for latent tuberculosis detection. The system, which was initially launched outside the U.S. in 2024, combines automation with high clinical accuracy in TB diagnostics.

The Auto-Pure 2400 platform features automated liquid handling and magnetic cell isolation technology, processing up to 24 samples per run and completing Day 1 testing in under 3.5 hours with minimal user interaction. The T-SPOT.TB test, recognized by WHO as the only ELISPOT-based IGRA, includes a cell number normalization step that ensures consistent results by reducing pre-analytical variables.

Key advantages include fewer indeterminate results, reduced repeat testing requirements, and reliable performance in immunocompromised patients.

Revvity (NYSE: RVTY) has expanded its partnership with Genomics England for the Generation Study, adding DNA sequencing services to their existing DNA extraction services. The collaboration aims to screen up to 100,000 newborns for over 200 rare genetic disorders through whole genome sequencing (WGS).

The company will provide an integrated end-to-end solution with a localized lab facility, enabling faster extraction and sequencing services. This research project, conducted in partnership with the National Health Service, will help inform future decisions on implementing WGS in newborn screening programs, potentially enabling earlier interventions and personalized care for pediatric-onset conditions.

Revvity (NYSE: RVTY) has announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG), expanding its infectious disease diagnostics portfolio. This novel assay is designed to support measles virus infection diagnosis and immune status determination.

The test is notable as the first commercial assay validated for dried blood spots (DBS) alongside traditional serum and plasma samples. DBS testing requires only fingertip blood droplets on paper cards, offering advantages in routine testing, studies, and regions with medical infrastructure.

The assay addresses a market gap as the first commercial solution for detecting anti-measles virus IgG antibodies using DBS samples, eliminating the need for laboratories to conduct their own validations. The test can be processed both manually and automatically using EUROIMMUN's scalable solutions.

Revvity (NYSE: RVTY) has secured a favorable ruling from the Massachusetts Superior Court, which will issue a permanent injunction enforcing its agreements with Cloud Software Group (CSG) regarding Spotfire® software. This follows a preliminary injunction from April 2024 and ensures continued access to Spotfire software and support for Revvity and its customers through 2034.

The ruling maintains Revvity's position as the exclusive provider of Spotfire in research and clinical markets, safeguarding operational continuity and service quality for customers. The company expressed satisfaction with the court's decision to uphold the agreements and emphasized its commitment to maintaining service reliability.

Revvity (NYSE: RVTY) has announced its participation in four major investor conferences during March 2025. The company's leadership team will present at the following events:

- 46th Annual Raymond James Institutional Investor Conference (March 3, 7:30 a.m. ET) featuring CFO Max Krakowiak
- TD Cowen 45th Annual Health Care Conference (March 4, 9:10 a.m. ET) with CEO Prahlad Singh
- Leerink Partners Global Healthcare Conference (March 11, 8:00 a.m. ET) featuring CEO Prahlad Singh
- KeyBanc Capital Markets Healthcare Forum (March 19, 9:00 a.m. ET) with Steve Willoughby, SVP of Investor Relations

The presentations will provide updates on the company's strategic priorities. Live audio webcasts will be available on the company's website, with replays accessible for at least 30 days following the events.

Revvity (NYSE: RVTY) reported strong fourth quarter 2024 results with revenue reaching $729 million, representing 5% reported growth and 6% organic growth. The company's Q4 GAAP EPS was $0.78, while adjusted EPS from continuing operations reached $1.42.

For full year 2024, GAAP revenue was $2,755 million compared to $2,751 million in 2023. The Life Sciences segment reported Q4 revenue of $336 million (5% growth), while Diagnostics segment achieved $393 million (4% growth).

Looking ahead, Revvity initiated its 2025 guidance with projected revenue of $2.80-$2.85 billion and adjusted EPS of $4.90-$5.00.